Expected with high hopes by all those affected by Alzheimer's and investors alike, the Phase 3 trial of Cassava Sciences' proprietary small molecule Simufilam failed to deliver the anticipated results. As a direct consequence, the company's shares dropped from around $26 to less than $4, with no comeback yet.